Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis

doi:10.3969/j.issn.1004-583X.2023.07.001

Abstract

Abstract:

Objective To evaluate the effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus (T2DM), and to elaborate its mechanism of action, so as to provide ideas and approaches for clinical diagnosis and treatment of T2DM. Methods Randomized controlled trials (RCTs) reporting the effect of probiotics on glucose metabolism in T2DM patients published before 31^st November 2022 were searched in the online databases of PubMed, Embase, Web of science, CNKI, Wanfang Data Knowledge Service Platform and CQVIP database were searched. Two investigators were independently responsible for literature screening. The included literatures were assessed and data were extracted and analyzed using RevMan 5.4 software. Results A total of 11 studies were included in the study, involving 709 T2DM patients. There were 371 T2DM patients in the experimental group and 338 in the control group. Meta-analysis showed that probiotic supplementation significantly reduced fasting plasma glucose (FPG), hemoglobin A1C (HbA₁C), homeostatic model assessment for insulin resistance (HOMA-IR), and fasting insulin levels in the experimental group than those in the control group. Conclusion Probiotic supplementation can improve glucose metabolism in T2DM patients, and probiotics can be used as one of the adjuvant treatments for T2DM patients.

Key words: diabetes mellitus, type 2, glucose metabolism, probiotics, meta-analysis

CLC Number:

R587.1

Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis[J]. Clinical Focus, 2023, 38(7): 581-587.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.07.001

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I7/581

Figures/Tables 11

References 24

[1]	World Health Organization Global Reports on Diabetes[R]. Geneva:WHO, 2016.
[2]	Barko PC, McMichael MA, Swanson KS, et al. The gastrointestinal microbiome: A review[J]. J Vet Intern Med, 2018, 32(1):9-25. doi: 10.1111/jvim.14875 pmid: 29171095
[3]	Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults[J]. PLoS One, 2010, 5(2):e9085. doi: 10.1371/journal.pone.0009085 URL
[4]	Lee S, Kirkland R, Grunewald ZI, et al. Beneficial effects of non-encapsulated or encapsulated probiotic supplementation on microbiota composition, intestinal barrier functions, inflammatory profiles, and glucose tolerance in high fat fed rats[J]. Nutrients, 2019, 11(9):1975. doi: 10.3390/nu11091975 URL
[5]	乐忠宏, 崔婷婷, 王朏朏, 等. 益生菌对2型糖尿病患者肠道菌群及胰岛素敏感性的影响[J]. 中国糖尿病杂志, 2022, 30(7):491-495.
[6]	Palacios T, Vitetta L, Coulson S, et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: A randomised controlled pilot study[J]. Nutrients, 2020, 12(7):2041. doi: 10.3390/nu12072041 URL
[7]	Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, et al. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study[J]. Clin Nutr. 2017, 36(1):85-92. doi: S0261-5614(15)00331-3 pmid: 26732026
[8]	Toejing P, Khampithum N, Sirilun S, et al. Influence of lactobacillus paracasei HII01 supplementation on glycemia and inflammatory biomarkers in type 2 diabetes: A randomized clinical trial[J]. Foods, 2021, 10(7):1455. doi: 10.3390/foods10071455 URL
[9]	Khalili L, Alipour B, Asghari Jafar-Abadi M, et al. The effects of lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus: A randomized controlled trial[J]. Iran Biomed J, 2019, 23(1):68-77. pmid: 29803203
[10]	Firouzi S, Majid HA, Ismail A, et al. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: A randomized controlled trial[J]. Eur J Nutr, 2017, 56(4):1535-1550. doi: 10.1007/s00394-016-1199-8 pmid: 26988693
[11]	Soleimani A, Zarrati Mojarrad M, Bahmani F, et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects[J]. Kidney Int, 2017, 91(2):435-442. doi: S0085-2538(16)30592-0 pmid: 27927601
[12]	Bayat A, Azizi-Soleiman F, Heidari-Beni M, et al. Effect of cucurbita ficifolia and probiotic yogurt consumption on blood glucose, lipid profile, and inflammatory marker in type 2 diabetes[J]. Int J Prev Med, 2016, 7:30. doi: 10.4103/2008-7802.175455 pmid: 26955460
[13]	Asemi Z, Alizadeh SA, Ahmad K, et al. Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial[J]. Clin Nutr, 2016, 35(4):819-825. doi: 10.1016/j.clnu.2015.07.009 pmid: 26209256
[14]	Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: A clinical trial[J]. Iran J Med Sci, 2013, 38(1):38-43.
[15]	Ostadrahimi A, Taghizadeh A, Mobasseri M, et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial[J]. Iran J Public Health, 2015, 44(2):228-237. pmid: 25905057
[16]	Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343:d5928. doi: 10.1136/bmj.d5928 URL
[17]	Sebastián Domingo JJ, Sánchez Sánchez C. From the intestinal flora to the microbiome[J]. Rev Esp Enferm Dig, 2018, 110(1):51-56. doi: 10.17235/reed.2017.4947/2017 pmid: 29271225
[18]	梁家琪, 刘恒旭, 阳金鑫, 等. 运动与肠道菌健康效益的关系[J]. 中国组织工程研究, 2022, 27(8): 1292-1299.
[19]	Vrieze A, Van NE, Holleman F, et al. Transfer of intestinal microbiota from lean donors increasesinsulin sensitivity in individuals with metabolic syndrome[J]. Gastroenterology, 2012, 143(4):913-916. doi: 10.1053/j.gastro.2012.06.031 pmid: 22728514
[20]	Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance[J]. Cell Metab, 2009, 9(4):311-326. doi: 10.1016/j.cmet.2009.02.002 pmid: 19356713
[21]	Asghari G, Farhadnejad H, Teymoori F, et al. High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults[J]. J Diabetes, 2018, 10(5):357-364. doi: 10.1111/1753-0407.12639 pmid: 29281182
[22]	Koh A, Molinaro A, Ståhlman M, et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1[J]. Cell, 2018, 175(4):947-961. doi: S0092-8674(18)31306-0 pmid: 30401435
[23]	Zheng X, Chen T, Jiang RI. Hyocholic acid species improve gluo se homeostasis through a distinct TGR5 and FXR signaling mechanism[J]. Cell Metab, 2021, 33(4):791-803. doi: 10.1016/j.cmet.2020.11.017 URL
[24]	Salamon D, Sroka-Oleksiak A, Kapusta P, et al. Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next-generation sequencing of the 16S rRNA gene fragment[J]. Pol Arch Intern Med, 2018, 128(6):336-343.

#1 2型糖尿病	#7 #1 and #3 in主题
#2益生菌	#8 #4 and #2 in主题
#3双歧杆菌	#9 #4 and #3 in主题
#4糖耐量受损	#10 (#1 or #4) and (#2 and #3) in主题
#6 #1 and #2 in主题	#11 (#1 or #4) and (#2 and #3) in摘要

#1 2型糖尿病	#7 #1 and #3 in主题
#2益生菌	#8 #4 and #2 in主题
#3双歧杆菌	#9 #4 and #3 in主题
#4糖耐量受损	#10 (#1 or #4) and (#2 and #3) in主题
#6 #1 and #2 in主题	#11 (#1 or #4) and (#2 and #3) in摘要

作者与年限	国家	干预组			对照组			干预方案		干预周期	结局指标	Cochrane 评分
		样本量 (例)		年龄 (岁)	样本量 (例)		年龄 (岁)	干预组	对照组
		样本量 (例)		年龄 (岁)	样本量 (例)		年龄 (岁)	乐忠宏^[5]2022	中国				80	59.4±6.1	45	58.1±5.3	二甲双胍+双歧杆菌四联活菌片 (3片/次,3次/d)	二甲双胍+保持饮食结构不变	12周	①②③	4分
Palacios^[6]2020	澳大利亚	14	61.4±8.9		14	56.1±12.3		二甲双胍+益生菌胶囊(含有植物乳杆菌Lp-115、保加利亚乳杆菌Lb-64、加氏乳杆菌Lg-36短双歧杆菌Bb-03、动物双歧杆菌lactisBi-07、双歧杆菌Bb-06、嗜热链球菌St-21、布拉氏酵母DBVPG 6763的胶囊)	二甲双胍+安慰剂(微晶纤维素,二氧化硅和硬脂酸镁)	12周	①②③④	5分
Tonucci^[7]2017	巴西	24	51.40±6.80		24	50.21±8.7		患者补充含有嗜酸乳杆菌La-5(6×10⁷ CFU/g)、乳酸双歧杆菌BB-12(2×10⁷CFU/g)的牛奶	补充安慰剂(牛奶)	6周	①②③④	5分
Toejing^[8]2021	泰国	18	61.78±7.73		18	63.50±5.94		补充含有益生菌的胶囊(副干酪乳杆菌HII01 50×10⁹CFU/g)	补充安慰剂(玉米淀粉)	12周	①②	4分
Khalili^[9]2019	伊朗	20	43.95±8.14		20	45±5.37		补充含有10⁸CFU/g干酪乳杆菌的胶囊	补充安慰剂(含有麦芽糖糊精)	8周	②③④	5分
Firouzi^[10]2017	伊朗	68	52.9±9.2		68	54.2±8.3		每包提供3×10¹⁰ CFU/g活微生物制剂粉末(其中每包粉末含有嗜酸乳杆菌,乳酸杆菌,双歧杆菌,长双歧杆菌)	补充安慰剂	12周	②③	5分
Alireza^[11]2017	伊朗	30	36~75		30	36~75		补充含有2×10⁹ CFU/g嗜酸乳杆菌、干酪乳杆菌、双歧双歧杆菌的胶囊	补充安慰剂	12周	①②③④	5分
Bayat^[12]2016	伊朗	20	46.95±9.34		20	54.1±9.54		补充含有益生菌的酸奶	饮食指导,保持饮食结构不变	8周	①②	4分
Asemi^[13]2015	伊朗	51	52.9±8.1		51	52.9±8.1		补充益生元的食品,其含有产孢乳杆菌1×10⁷ CFU/g	补充对照食品(不含益生菌)	6周	③④	5分
Mazloom^[14]2013	伊朗	16	55.4±8		18	51.8±10.2		补充含有嗜酸乳杆菌、保加利亚乳杆菌、双歧乳杆菌和干酪乳杆菌的胶囊	补充含有硬脂酸镁的胶囊	6周	①③	4分
Ostadrahimi^[15]2015	伊朗	30	48.29±11.71		30	51.4±8.6		补充600 ml有益生菌的发酵乳(其含有嗜酸乳杆菌、干酪乳杆菌、双歧杆菌)	补充600 ml普通乳品	8周	①③	4分

作者与年限	国家	干预组			对照组			干预方案		干预周期	结局指标	Cochrane 评分
		样本量 (例)		年龄 (岁)	样本量 (例)		年龄 (岁)	干预组	对照组
		样本量 (例)		年龄 (岁)	样本量 (例)		年龄 (岁)	乐忠宏^[5]2022	中国				80	59.4±6.1	45	58.1±5.3	二甲双胍+双歧杆菌四联活菌片 (3片/次,3次/d)	二甲双胍+保持饮食结构不变	12周	①②③	4分
Palacios^[6]2020	澳大利亚	14	61.4±8.9		14	56.1±12.3		二甲双胍+益生菌胶囊(含有植物乳杆菌Lp-115、保加利亚乳杆菌Lb-64、加氏乳杆菌Lg-36短双歧杆菌Bb-03、动物双歧杆菌lactisBi-07、双歧杆菌Bb-06、嗜热链球菌St-21、布拉氏酵母DBVPG 6763的胶囊)	二甲双胍+安慰剂(微晶纤维素,二氧化硅和硬脂酸镁)	12周	①②③④	5分
Tonucci^[7]2017	巴西	24	51.40±6.80		24	50.21±8.7		患者补充含有嗜酸乳杆菌La-5(6×10⁷ CFU/g)、乳酸双歧杆菌BB-12(2×10⁷CFU/g)的牛奶	补充安慰剂(牛奶)	6周	①②③④	5分
Toejing^[8]2021	泰国	18	61.78±7.73		18	63.50±5.94		补充含有益生菌的胶囊(副干酪乳杆菌HII01 50×10⁹CFU/g)	补充安慰剂(玉米淀粉)	12周	①②	4分
Khalili^[9]2019	伊朗	20	43.95±8.14		20	45±5.37		补充含有10⁸CFU/g干酪乳杆菌的胶囊	补充安慰剂(含有麦芽糖糊精)	8周	②③④	5分
Firouzi^[10]2017	伊朗	68	52.9±9.2		68	54.2±8.3		每包提供3×10¹⁰ CFU/g活微生物制剂粉末(其中每包粉末含有嗜酸乳杆菌,乳酸杆菌,双歧杆菌,长双歧杆菌)	补充安慰剂	12周	②③	5分
Alireza^[11]2017	伊朗	30	36~75		30	36~75		补充含有2×10⁹ CFU/g嗜酸乳杆菌、干酪乳杆菌、双歧双歧杆菌的胶囊	补充安慰剂	12周	①②③④	5分
Bayat^[12]2016	伊朗	20	46.95±9.34		20	54.1±9.54		补充含有益生菌的酸奶	饮食指导,保持饮食结构不变	8周	①②	4分
Asemi^[13]2015	伊朗	51	52.9±8.1		51	52.9±8.1		补充益生元的食品,其含有产孢乳杆菌1×10⁷ CFU/g	补充对照食品(不含益生菌)	6周	③④	5分
Mazloom^[14]2013	伊朗	16	55.4±8		18	51.8±10.2		补充含有嗜酸乳杆菌、保加利亚乳杆菌、双歧乳杆菌和干酪乳杆菌的胶囊	补充含有硬脂酸镁的胶囊	6周	①③	4分
Ostadrahimi^[15]2015	伊朗	30	48.29±11.71		30	51.4±8.6		补充600 ml有益生菌的发酵乳(其含有嗜酸乳杆菌、干酪乳杆菌、双歧杆菌)	补充600 ml普通乳品	8周	①③	4分